Improved blood tests for cancer screening: General or specific?

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Cree, Ian A ^a  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; RNA; CA 125 ANTIGEN; TUMOR MARKER;

APOPTOSIS; BLOOD EXAMINATION; BREAST CANCER; CANCER CELL; CANCER CLASSIFICATION; CANCER PATIENT; CANCER SCREENING; CELL COUNT; CELL GROWTH; CELL SURVIVAL; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; NOTE; OVARY CANCER; SCREENING TEST; UTERINE CERVIX CANCER; BLOOD; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; NEOPLASM; SENSITIVITY AND SPECIFICITY;

CA-125 ANTIGEN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 82255173787     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-499     Document Type: Note

References (42)

1. Ahlquist DA, Sargent DJ, Loprinzi CL, Levin TR, Rex DK, Ahnen DJ, Knigge K, Lance MP, Burgart LJ, Hamilton SR, Allison JE, Lawson MJ, Devens ME, Harrington JJ, Hillman SL. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med 2008, 149:441-450. W81.
2. Vinnicombe S, Pinto Pereira SM, McCormack VA, Shiel S, Perry N, Dos Santos Silva IM. Full-field digital versus screen-film mammography: comparison within the UK breast screening program and systematic review of published data. Radiology 2009, 251:347-358. 10.1148/radiol.2512081235, 19401569.
3. Kitchener HC, Blanks R, Cubie H, Desai M, Dunn G, Legood R, Gray A, Sadique Z, Moss S, . MAVARIC Trial Study Group MAVARIC: a comparison of automation-assisted and manual cervical screening: a randomised controlled trial. Health Technol Assess 2011, 15:iii-iv. ix-xi, 1-170, MAVARIC Trial Study Group.
4. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Iftner T, . Joint European Cohort Study Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008, 337:a1754. 10.1136/bmj.a1754, 2658827, 18852164, Joint European Cohort Study.
5. Zeliadt SB, Hoffman RM, Etzioni R, Gore JL, Kessler LG, Lin DW. Influence of publication of US and European prostate cancer screening trials on PSA testing practices. J Natl Cancer Inst 103:520-523.
6. Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981, 68:1331-1337. 10.1172/JCI110380, 370929, 7028788.
7. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Singh N, Dawnay A, Skates SJ, Parmar M, Jacobs I. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009, 10:327-340. 10.1016/S1470-2045(09)70026-9, 19282241.
8. Tiss A, Timms JF, Smith C, Devetyarov D, Gentry-Maharaj A, Camuzeaux S, Burford B, Nouretdinov I, Ford J, Luo Z, Jacobs I, Menon U, Gammerman A, Cramer R. Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling. Int J Gynecol Cancer 2011, 20:1518-1524.
9. Hanash SM, Baik CS, Kallioniemi O. Emerging molecular biomarkers: blood-based strategies to detect and monitor cancer. Nat Rev Clin Oncol 2011, 8:142-150. 10.1038/nrclinonc.2010.220, 21364687.
10. Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
11. Bast RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005, 15(Suppl 3):274-281.
12. Asiago VM, Alvarado LZ, Shanaiah N, Gowda GA, Owusu-Sarfo K, Ballas RA, Raftery D. Early detection of recurrent breast cancer using metabolite profiling. Cancer Res 2010, 70:8309-8318. 10.1158/0008-5472.CAN-10-1319, 2995269, 20959483.
13. Tiziani S, Lopes V, Günther UL. Early stage diagnosis of oral cancer using 1H NMR-based metabolomics. Neoplasia 2009, 11:269-276. 2647729, 19242608.
14. Nordström A, Lewensohn R. Metabolomics: moving to the clinic. J Neuroimmune Pharmacol 2010, 5:4-17. 10.1007/s11481-009-9156-4, 19399626.
15. Johansson M, McKay JD, Rinaldi S, Wiklund F, Adami HO, Grönberg H, Kaaks R, Stattin P. Genetic and plasma variation of insulin-like growth factor binding proteins in relation to prostate cancer incidence and survival. Prostate 2009, 69:1281-1291. 10.1002/pros.20972, 19455605.
16. Carbone A, Rodeck U, Mauri FA, Sozzi M, Gaspari F, Smirne C, Prati A, Addeo A, Novarino A, Robecchi A, Bertetto O, Emanuelli G, Bellone G. Human pancreatic carcinoma cells secrete bioactive interleukin-18 after treatment with 5-fluorouracil: implications for anti-tumor immune response. Cancer Biol Ther 2005, 4:231-241. 10.4161/cbt.4.2.1476, 15684607.
17. Ueno T, Toi M, Linder S. Detection of epithelial cell death in the body by cytokeratin 18 measurement. Biomed Pharmacother 2005, 59(Suppl 2):S359-S362.
18. Inaba N, Negishi Y, Fukasawa I, Okajima Y, Ota Y, Tanaka K, Matsui H, Iwasaki H, Sudo H, Tanaka N, Pakk C, Suzuki N, Sekiya S. Cytokeratin fragment 21-1 in gynecologic malignancy: comparison with cancer antigen 125 and squamous cell carcinoma-related antigen. Tumor Biol 1995, 16:345-352.
19. Wang J, Yi Y, Li B, Wang Z, Sun H, Zhang P, Huang W. CYFRA21-1 can predict the sensitivity to chemoradiotherapy of non-small-cell lung carcinoma. Biomarkers 2010, 15:594-601. 10.3109/1354750X.2010.504308, 20649505.
20. Chen Z, Feng J, Buzin CH, Liu Q, Weiss L, Kernstine K, Somlo G, Sommer SS. Analysis of cancer mutation signatures in blood by a novel ultra-sensitive assay: monitoring of therapy or recurrence in non-metastatic breast cancer. PLoS One 2009, 4:e7220. 10.1371/journal.pone.0007220, 2749210, 19789704.
21. Board RE, Wardley AM, Dixon JM, Armstrong AC, Howell S, Renshaw L, Donald E, Greystoke A, Ranson M, Hughes A, Dive C. Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Res Treat 2011, 120:461-467.
22. Dobrzycka B, Terlikowski SJ, Mazurek A, Kowalczuk O, Niklinska W, Chyczewski L, Kulikowski M. Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancer. Int J Cancer 2010, 127:612-621. 10.1002/ijc.25077, 19960433.
23. Liggett T, Melnikov A, Yi QL, Replogle C, Brand R, Kaul K, Talamonti M, Abrams RA, Levenson V. Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis. Cancer 2010, 116:1674-1680. 10.1002/cncr.24893, 20143430.
24. Ho AS, Huang X, Cao H, Christman-Skieller C, Bennewith K, Le QT, Koong AC. Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl Oncol 2003, 3:109-113.
25. Iguchi H, Kosaka N, Ochiya T. Secretory microRNAs as a versatile communication tool. Commun Integr Biol 2010, 3:478-481. 10.4161/cib.3.5.12693, 2974086, 21057646.
26. Zomer A, Vendrig T, Hopmans ES, van Eijndhoven M, Middeldorp JM, Pegtel DM. Exosomes: fit to deliver small RNA. Commun Integr Biol 2010, 3:447-450. 10.4161/cib.3.5.12339, 2974077, 21057637.
27. Orozco AF, Lewis DE. Flow cytometric analysis of circulating microparticles in plasma. Cytometry A 2010, 77:502-514. 2919894, 20235276.
28. Wu FTH, Stefanini MO, Mac Gabhann F, Kontos CD, Annex BH, Popel AS. A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med 2010, 14:528-552. 3039304, 19840194.
29. Chouaib S, Kieda C, Benlalam H, Noman MZ, Mami-Chouaib F, Rüegg C. Endothelial cells as key determinants of the tumor microenvironment: interaction with tumor cells, extracellular matrix and immune killer cells. Crit Rev Immunol 2010, 30:529-545.
30. Taylor DD, Gercel-Taylor C, Parker LP. Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol Oncol 2009, 115:112-120. 10.1016/j.ygyno.2009.06.031, 2760307, 19647308.
31. Nakagawa T, Martinez SR, Goto Y, Koyanagi K, Kitago M, Shingai T, Elashoff DA, Ye X, Singer FR, Giuliano AE, Hoon DSB. Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes. Clin Cancer Res 2007, 13:4105-4110. 10.1158/1078-0432.CCR-07-0419, 17634536.
32. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, Kinzler KW, Vogelstein B, Diaz LA. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008, 14:985-990. 10.1038/nm.1789, 2820391, 18670422.
33. Sunami E, Vu AT, Nguyen SL, Giuliano AE, Hoon DSB. Quantification of LINE1 in circulating DNA as a molecular biomarker of breast cancer. Ann N Y Acad Sci 2008, 1137:171-174. 10.1196/annals.1448.011, 18837943.
34. Moreira VG, Prieto B, Rodríguez JS, Alvarez FV. Usefulness of cell-free plasma DNA, procalcitonin and C-reactive protein as markers of infection in febrile patients. Ann Clin Biochem 2010, 47:253-258. 10.1258/acb.2010.009173, 20421309.
35. Zhong XY, von Mühlenen I, Li Y, Kang A, Gupta AK, Tyndall A, Holzgreve W, Hahn S, Hasler P. Increased concentrations of antibody-bound circulatory cell-free DNA in rheumatoid arthritis. Clin Chem 2007, 53:1609-1614. 10.1373/clinchem.2006.084509, 17712000.
36. Glasziou PP, Irwig L, Heritier S, Simes RJ, Tonkin A, . LIPID Study Investigators Monitoring cholesterol levels: measurement error or true change?. Ann Intern Med 2008, 148:656-661. LIPID Study Investigators.
37. Künzli BM, Friess H, Shrikhande SV. Is laparoscopic colorectal cancer surgery equal to open surgery? An evidence based perspective. World J Gastrointest Surg 2010, 2:101-108. 10.4240/wjgs.v2.i4.101, 2999223, 21160858.
38. Green S, Tawil A, Barr H, Bennett C, Bhandari P, Decaestecker J, Ragunath K, Singh R, Jankowski J. Surgery versus radical endotherapies for early cancer and high grade dysplasia in Barrett's oesophagus. Cochrane Database Syst Rev 2009, 2:CD007334.
39. Hoff G, Dominitz JA. Contrasting US and European approaches to colorectal cancer screening: which is best?. Gut 2010, 59:407-414. 10.1136/gut.2009.192948, 20207645.
40. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2011, 1:CD001877.
41. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC, Skates SJ. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009, 112:40-46. 10.1016/j.ygyno.2008.08.031, 18851871.
42. Pirmohamed M. Acceptance of biomarker-based tests for application in clinical practice: criteria and obstacles. Clin Pharmacol Ther 2010, 88:862-866. 10.1038/clpt.2010.245, 20981006.